<DOC>
	<DOCNO>NCT00724854</DOCNO>
	<brief_summary>The objective study evaluate , group , number participant achieve rapid virological response ( RVR ) 4 week treatment PegIntron Rebetol . The study also assess whether RVR reliable predictor sustain virologic response ( define undetectable viral load 24 week post-treatment ) .</brief_summary>
	<brief_title>Evaluation Rapid Virologic Response Among HCV Patients Treated With PegIntron Rebetol Brazil ( Study P05427 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Willing participate study sign Informed Consent Form Established HCV infection , confirm molecular biology test ( positive qualitative polymerase chain reaction [ PCR ] test ) Can treatmentna√Øve , retreatment , coinfected HIV Be treatment PegIntron combination ribavirin , start 14 day screen visit Participants confirm willingness participate study refuse sign Free Informed Consent Form Prior treatment PegIntron ( combine ribavirin ) History alcohol abuse past 6 month Decompensated liver disease Severe heart disease Decompensated thyroid disorder Neoplasia Type 1 diabetes mellitus uncontrolled hardly control Seizures uncontrolled Primary immune deficiency Men woman use appropriate contraceptive method Pregnancy lactation For participant coinfected HIV : HIVrelated opportunistic disease past 6 month CD4 count low 200 cells/mm^3</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>